Short Sellers Become More Selective on Major Biotechs

Photo of Chris Lange
By Chris Lange Updated Published
Short Sellers Become More Selective on Major Biotechs

© Thinkstock

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. In fact, a cure or incredible new breakthrough in cancer or Alzheimer’s disease will be worth more than any risks from Brexit or political rhetoric from the campaign trail.

FDA rulings can make or break the biotech sector, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock then some short sellers can argue for a stock implosion down the road.

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.

[nativounit]

Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 7.80 million shares from the previous level of 7.20 million. Shares closed most recently at $161.96, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.49 million shares from the previous 2.20 million. The stock closed Tuesday at $253.36, within a 52-week range of $223.02 to $412.24.

Celgene Corp. (NASDAQ: CELG) short interest for this settlement date decreased slightly to 8.31 million shares from the previous 8.40 million. Shares closed most recently at $103.41, in a 52-week range of $92.98 to $140.72.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest decrease to 22.21 million shares from 24.70 million in the previous period. Shares closed Tuesday at $86.63, in a 52-week trading range of $77.92 to $120.37.

MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 85.96 million shares. The previous reading was 81.40 million. Shares closed most recently at $1.13, in a 52-week trading range of $0.64 to $5.80.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased ever so slightly to 4.74 million, compared to the previous level of 4.75 million. Shares closed most recently at $125.35, in a 52-week range of $110.56 to $208.88.

[wallst_email_signup]

Contact [email protected] for any questions or corrections.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

ABNB Vol: 15,875,803
MCHP Vol: 18,948,103
PLTR Vol: 76,296,940
MRNA Vol: 6,804,179
AXON Vol: 1,578,308

Top Losing Stocks

TTD Vol: 132,975,248
CTRA Vol: 73,319,495
AKAM Vol: 7,991,805
ZTS Vol: 12,755,470
RMD Vol: 3,775,013